Moreover, the function of CD8+ T cells was also remarkedly improved by the combination therapy of OVA@SVMAV and aPD-1, as indicated by the flow cytometry analysis of IFNγ+ CD8+ T cells in tumor (online supplemental figure S5). The gene discussed is CD8A; the disease is neoplasm.